The topic of my research is model-based personalized medicine in oncology/hematology. My overall research ambition stems from the need to improve efficacy and reduce toxicity of anticancer drug therapy through the application of quantitative pharmacology. In my research, I aim to use pharmacokinetic/pharmacodynamic (PKPD) modeling to integrate information on systemic exposure, tissue penetration, cellular and/or molecular engagement and expression of pharmacological activity with long term response (efficacy & toxicity). I authored more than 55 manuscripts in peer-reviewed journals (>20 as first/last author) in the field of  target site pharmacokinetic-pharmacodynamic modeling to optimize cancer treatment.

For this research goal, we have established a network of researchers interested in target site penetration measurements, with expertise in therapeutic plasma PK-sampling, PET scans using inert radiolabeled small molecule radiopharmaceuticals, real-time MRI perfusion scans and structured databases of clinical outcomes. Here, we combine relevant preclinical mechanistic data of physicochemical drug properties related to PK and efficacy/toxicity, pathologic and physiological factors and apply mathematics to describe the mechanisms that control the uptake, distribution, and elimination of drug into blood and (tumor) tissues. When adequately evaluated using relevant and quantified target site-measurements, this information can bridge the gap between the therapeutic regimen and the pharmacological link with clinical outcome.

Small molecules, oncology & hematology, model-based personalized medicine, pharmacokinetic/pharmacodynamic (PKPD) modeling,  physiology-based pharmacokinetic modeling